Business
Hoth Therapeutics, Inc.: If we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.
Net income decreased 52.3% to ($12.5M), while Operating cash flow decreased 40.5% to ($9.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($12.5M)Watch
- Cash generation — Free cash flow ($9.8M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Rocket One Inc.'s own filings, the day they're filed.
- Wayne Linsley · departureeff. 2025-04-15
- Accrued Salary · departure
- Accrued Benefits · departure
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-21
- 8-K · Company announcement2026-06-25
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Rocket One Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.